Medivir AB (STO: MVIRB), a medical research company, reported on Wednesday a negative earnings per diluted share of SEK3.88 for the second quarter of 2018, from April 2018 to June 201.
This was an improvement over a negative EPS of SEK3.91 per diluted share, in Q2 2017.
Loss before interest, tax, depreciation and amortisation (EBITDA) for the quarter totaled a negative SEK89.9m, an improvement over a negative SEK90.9m, in Q2 2017.
Net turnover for the quarter totalled SEK2.8m, as compared with SEK9.5m in Q2 2017.
Medivir develops new drugs and pharmaceutical compounds based on proteases and polymerases as target enzymes. Medivir focuses on infectious and immunological diseases including projects against HIV, jaundice, shingles, multiple sclerosis and rheumatoid arthritis.
(EUR1.00=SEK10.26)
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results